The Antibody That Just Dethroned Trastuzumab in Stomach Cancer

Crucially, the benefit held up across subgroups, including patients regardless of PD-L1 status. That matters because PD-L1 testing can be unreliable, and a drug that works across biomarker categories simplifies treatment decisions.

A Molecule That Fights Differently

So what makes Ziihera different from trastuzumab? Think of HER2, the protein on the cancer cell's surface, as a door with two locks. Trastuzumab only has one key. Zanidatamab, built on Zymeworks' Azymetric platform, carries two keys that fit two distinct spots (epitopes) on HER2 simultaneously. This "biparatopic" design triggers a cascade of effects: it blocks HER2 signaling from two angles, forces the cancer cell to pull HER2 off its own surface (stripping the cell of its growth signals), and recruits the immune system through multiple pathways including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

In plain English: it attacks the tumor's favorite protein from multiple directions at once, then calls in reinforcements. Trastuzumab, by comparison, is a one-key, one-lock approach developed in the early 2000s.

Jazz's Long Game Pays Off

Jazz didn't build zanidatamab from scratch. The molecule was engineered by Zymeworks, and in October 2022, Jazz signed an exclusive licensing deal to develop and sell it in the U.S., Europe, Japan, and most other markets. The upfront price was $50 million, which looked modest at the time. Then, just two months later, Jazz exercised its option to deepen the partnership, triggering a $325 million payment.

That bet is starting to look brilliant. Ziihera already picked up an accelerated approval in 2024 for previously treated HER2-positive biliary tract cancer (a rare bile duct cancer). Now the gastric approval opens the door to a much larger, more competitive market.

The Competitive Chessboard Just Got Interesting

HER2-positive gastric cancer is a niche within a niche: only a fraction of all stomach cancers overexpress HER2. But the drugs fighting for that niche are some of the most watched molecules in oncology.

Trastuzumab deruxtecan (T-DXd, sold as Enhertu) by Daiichi Sankyo and AstraZeneca has dominated the HER2 conversation, particularly in second-line treatment after trastuzumab fails. Analysts expect it to maintain the highest revenue in this segment through at least 2034. Meanwhile, disitamab vedotin, a HER2-targeted antibody-drug conjugate already approved in China, is pressing westward.

Zanidatamab's angle is different. Rather than competing as another ADC (antibody-drug conjugate, basically a guided missile that delivers chemo directly to the tumor), it's a bispecific antibody that fights in the first-line setting, right where trastuzumab has been king. Analyst reports consistently frame Ziihera as the most significant near-term challenger to trastuzumab's grip on first-line treatment.

The landscape is evolving from a monopoly into something more like a three-way race: trastuzumab holding legacy share, T-DXd dominating later lines and expanding forward, and zanidatamab carving out a first-line beachhead with survival data that neither competitor has matched in a head-to-head phase 3 setting.

Why This Matters Beyond Stomach Cancer

This approval is a proof of concept for bispecific antibodies in solid tumors. Most bispecific success stories so far have been in blood cancers. Showing that a bispecific can beat a well-established monoclonal antibody in a randomized phase 3 trial, with an overall survival win no less, raises the ceiling for the entire drug class.

For Jazz, it validates a strategy of licensing late-stage assets rather than building from scratch. For patients, it offers a meaningfully better first option than the one they've had for twenty years.

And for trastuzumab? It's not going away tomorrow. But for the first time, it has a genuine rival at the front of the line. The era of one-size-fits-all HER2 therapy in gastric cancer is officially over.

The Biotech Investor That Got Caught Peeking at the Answer Key

A federal court found RA Capital and Avilar Therapeutics guilty of willfully stealing a trade secret from Yale, awarding $4 million to Biohaven and the university. The verdict could reshape how biotech investors handle confidential academic science forever.